{
    "clinical_study": {
        "@rank": "79061", 
        "arm_group": {
            "arm_group_label": "Liraglutide / Sitagliptin"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this study is to investigate a retrospective\n      database assessment of clinical effectiveness in type 2 diabetes patients treated with\n      liraglutide from primary care centers in Sweden."
        }, 
        "brief_title": "A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients from EMR (electronic medical record) system in the primary care in Sweden\n\n          -  Patients equal to or more than 18 years of age\n\n          -  Starting treatment with liraglutide or sitagliptin from January 2010 to December 2013\n\n          -  Minimum of 180 days of prior follow-up/history within the database before their index\n             date\n\n        Exclusion Criteria:\n\n          -  Patients with cancer, end stage liver disease, end stage renal failure (non-diabetes\n             related)\n\n          -  Female patients with gestational diabetes during pregnancy\n\n          -  Patients with previous GLP-1 (glucagon-like peptide-1) or DPP-IV (dipeptidyl\n             peptidase-4 ) inhibitor use, i.e. patients should be incretin na\u00efve"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Data will be analyzed for patients with type 2 diabetes treated with liraglutide or\n        sitagliptin from January 2010 to December 2013, with a treatment length of 180 days."
            }
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077946", 
            "org_study_id": "NN2211-4161", 
            "secondary_id": "U1111-1151-9632"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liraglutide / Sitagliptin", 
                "description": "No treatment given.", 
                "intervention_name": "liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Liraglutide / Sitagliptin", 
                "description": "No treatment given.", 
                "intervention_name": "sitagliptin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon-Like Peptide 1", 
                "Sitagliptin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 9, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Malm\u00f6", 
                    "country": "Sweden", 
                    "zip": "202 15"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction", 
            "safety_issue": "No", 
            "time_frame": "Day 0, Day 180"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077946"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent (%) of patients with HbA1c (glycosylated haemoglobin) reduction  at least 1 %-point and weight reduction at least 3% (NICE clinical guidelines, liraglutide only)", 
                "safety_issue": "No", 
                "time_frame": "Day 0, Day 180"
            }, 
            {
                "measure": "HbA1c (NGSP standard, in %) change", 
                "safety_issue": "No", 
                "time_frame": "Day 0, Day 180"
            }, 
            {
                "measure": "Change in weight (in kilograms)", 
                "safety_issue": "No", 
                "time_frame": "Day 0, Day 180"
            }, 
            {
                "measure": "Change in blood pressure (systolic, in mmHg)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 180 days of therapy"
            }, 
            {
                "measure": "Change in lipids (HDL, LDL and triglycerides, in mmol/L)", 
                "safety_issue": "No", 
                "time_frame": "Day 0, Day 180"
            }, 
            {
                "measure": "Change in creatinine", 
                "safety_issue": "No", 
                "time_frame": "Day 0, Day 180"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}